Investor Alert

April 9, 2020, 2:07 a.m. EDT

CAR-T Cell Therapy Market Share 2020 Global Industry Share, Growth, Trend, Demand, Top Players, Opportunities and Forecast to 2026

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Apr 09, 2020 Xherald -- Market Study Report adds 2020-2026 Global CAR-T Cell Therapy report that offers an exhaustive coverage of the industry with brief analysis, data charts, figures, statistics that help take business decisions, company profiles and more.

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by The marker research report. The report "CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 - 2026" provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.

Request a sample of this premium report at: https://www.marketstudyreport.com/request-a-sample/1695130/?utm_source=Americanewshour.com-AN

Some major key players in global CAR-T Cell Therapy Market includes Bluebird Bio (US), Celgene Corporation (US), Gilead Sciences, Inc. (US), Cellectis (France), Servier Laboratories (France), Pfizer Inc. (US), Mereck KGaA (Germany), Amgen Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Caribou Biosciences, Inc. (US), Celyad (Belgium), Bellicum Pharmaceuticals, Inc. (US), Noile-Immune Biotech (Japan), Nanjing Legend Biotechnology Co., Ltd. (China), Johnson & Johnson (US), Sangamo Therapeutics, Inc. (US) among others.

According to the analysis by The marker research report, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21. However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.

It is estimated that U.S. is one of the major markets for CAR-T Cell Therapy due to continuous R&D happening in this region also backed by ongoing regulatory approvals of the new therapies. Along with the new therapy developments, companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment. This would help the market to grow in this region. The European region is also expected to closely follow by U.S. wherein European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth in this region. However, the market for Asia Pacific is at its early stages wherein Ministry of Health, Labor and Welfare (MHLW) of Japan is the first regulatory authority to approve Kymriah in APAC.

Along with opening new centers and acquiring necessary government approvals, the companies are also focusing on partnerships, acquisitions and mergers. For instance, Celgene acquired Juno Therapeutics in November 2018 for approximately $9 billion in 2018 and further Bristol-Myers Squibb completed its acquisition of Celgene in November 2019.

Request a discount on standard prices of this premium report at: https://www.marketstudyreport.com/check-for-discount/1695130/?utm_source=Americanewshour.com-AN

This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients' immune cells to fight cancer. The WBCs (white blood cells) are extracted - reengineered - injected again into the patient body to fight the malignant cells. This novel therapy has joined the bandwagon of the cancer cure treatments and it is expected to be one the sought-after therapies in the market. Majority of the companies have already started investing in them to gain a better market share in this industry.

Table of Content:

Chapter 1. Overview and Scope

Chapter 2. Executive Summary

Chapter 3. CAR-T Cell Therapy Market - Premium Insights

Chapter 4. CAR-T Cell Therapy Market Size and Forecast 2017 - 2026 by Target Antigen

Chapter 5. CAR-T Cell Therapy Market Size and Forecast by Indication

Chapter 6. CAR-T Cell Therapy Market Size and Forecast by Regions

Chapter 7. Company Profiles

For More Details on this Report At: https://www.marketstudyreport.com/reports/car-t-cell-therapy-market-by-target-antigen-cd19-cd20-meso-her2-egfrv-iii-and-others-by-application-acute-lymphoblastic-leukemia-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-multiple-myeloma-and-others-and-by-regions-market-size-forecast-2018-2025

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.